This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.
Hortobagy GN, Ames FC, Buzdar AU, Kau SW, McNeese MD, Paulus D, et al. Management of stage III primary breast cancer with primary chemotherapy, surgery, and radiation therapy. Cancer 1988; 62: 2507-16.HortobagyGNAmesFCBuzdarAUKauSWMcNeeseMDPaulusDManagement of stage III primary breast cancer with primary chemotherapy, surgery, and radiation therapyCancer19886225071610.1002/1097-0142(19881215)62:12<2507::AID-CNCR2820621210>3.0.CO;2-DSearch in Google Scholar
Mauriac L, Durand M, Avril A, Dilhuydy JM. Effects of primary chemotherapy in conservative treatment of breast cancer patients with operable tumors larger than 3 cm: Results of a randomized trial in a single centre. Ann Oncol 1991; 2: 347-54.MauriacLDurandMAvrilADilhuydyJMEffects of primary chemotherapy in conservative treatment of breast cancer patients with operable tumors larger than 3 cm: Results of a randomized trial in a single centreAnn Oncol199123475410.1093/oxfordjournals.annonc.a057953Search in Google Scholar
Schwartz GF, Birchansky CA, Komarnicky LT, Mansfield CM, Cantor RI, Biermann WA, et al. Induction chemotherapy followed by breast conservation for locally advanced carcinoma of the breast. Cancer 1994; 73: 362-9.SchwartzGFBirchanskyCAKomarnickyLTMansfieldCMCantorRIBiermannWAInduction chemotherapy followed by breast conservation for locally advanced carcinoma of the breastCancer199473362910.1002/1097-0142(19940115)73:2<362::AID-CNCR2820730221>3.0.CO;2-LSearch in Google Scholar
Calais G, Berger C, Descamps P, Chapet S, Reynaud-Bougnoux A, Body G, et al. Conservative treatment feasibility with induction chemotherapy , surgery, and radiotherapy for patients with breast carcinoma larger than 3 cm. Cancer 1994; 74: 1283-8.CalaisGBergerCDescampsPChapetSReynaud-BougnouxABodyGConservative treatment feasibility with induction chemotherapy , surgery, and radiotherapy for patients with breast carcinoma larger than 3 cmCancer1994741283810.1002/1097-0142(19940815)74:4<1283::AID-CNCR2820740417>3.0.CO;2-SSearch in Google Scholar
Singletary SE, McNeese MD, Hortobagyi GN. Feasibility of breast-conservation surgery after induction chemotherapy for locally advanced breast carcinoma. Cancer 1992; 69: 2849-52.SingletarySEMcNeeseMDHortobagyiGNFeasibility of breast-conservation surgery after induction chemotherapy for locally advanced breast carcinomaCancer19926928495210.1002/1097-0142(19920601)69:11<2849::AID-CNCR2820691134>3.0.CO;2-PSearch in Google Scholar
Kuerer HM, Newman LA, Smith TL, Ames FC, Hunt KK, Dhingra K, et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 1999; 17: 460-9.KuererHMNewmanLASmithTLAmesFCHuntKKDhingraKClinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapyJ Clin Oncol199917460910.1200/JCO.1999.17.2.460Search in Google Scholar
van der Hage JA, van de Velde CJ, Julien JP, Tubiana-Hulin M, Vandervelden C, Duchateau L. Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer Trial 10902. J Clin Oncol 2001; 19: 4224-37.van der HageJAvan de VeldeCJJulienJPTubiana-HulinMVanderveldenCDuchateauLPreoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer Trial 10902J Clin Oncol20011942243710.1200/JCO.2001.19.22.4224Search in Google Scholar
Bear HD, Anderson S, Brown A, Smith R, Mamounas EP, Fisher B, et al. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide. Preliminary results from NSABP B-27. J Clin Oncol 2003; 21: 4165-74.BearHDAndersonSBrownASmithRMamounasEPFisherBThe effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide. Preliminary results from NSABP B-27J Clin Oncol20032141657410.1200/JCO.2003.12.005Search in Google Scholar
Bear HD, Anderson S, Smith RE, Geyer CE Jr, Mamounas EP, Fisher B, et al. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 2006; 24: 2019-27.BearHDAndersonSSmithREGeyerCEJrMamounasEPFisherBSequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27J Clin Oncol20062420192710.1200/JCO.2005.04.1665Search in Google Scholar
Scholl SM, Fourquet A, Asselain B, Pierga JY, Vilcoq JR, Durand JC, et al. Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumours considered too large for breast conserving surgery: Preliminary results of a randomized trial: S6. Eur J Cancer 1994; 30A: 645-52.SchollSMFourquetAAsselainBPiergaJYVilcoqJRDurandJCNeoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumours considered too large for breast conserving surgery: Preliminary results of a randomized trial: S6Eur J Cancer199430A6455210.1016/0959-8049(94)90537-1Search in Google Scholar
Fisher B, Bryant J, Wolmark N, Mamounas E, Brown A, Fisher ER, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 1998; 16: 2672-85.FisherBBryantJWolmarkNMamounasEBrownAFisherEREffect of preoperative chemotherapy on the outcome of women with operable breast cancerJ Clin Oncol19981626728510.1200/JCO.1998.16.8.2672Search in Google Scholar
Mauriac L, Macgrogan G, Avril A, Durand M, Floquet A, Debled M, et al. Neoadjuvant chemotherapy for operable breast breast carcinoma larger than 3 cm: a unicenter randomized trial with a 124 month median follow up. Am Oncol 1999; 10: 47-52.MauriacLMacgroganGAvrilADurandMFloquetADebledMNeoadjuvant chemotherapy for operable breast breast carcinoma larger than 3 cm: a unicenter randomized trial with a 124 month median follow upAm Oncol199910475210.1023/A:1008337009350Search in Google Scholar
Feldman LD, Hortobagyi GN, Buzdar AU, Ames FC, Blumenschain GR. Pathologic assessment of response to induction chemotherapy in breast cancer. Cancer Res 1986; 46: 2578-81FeldmanLDHortobagyiGNBuzdarAUAmesFCBlumenschainGRPathologic assessment of response to induction chemotherapy in breast cancerCancer Res198646257881Search in Google Scholar
Chollet P, Charrier S, Brain E, Curé H, van Praagh I, Feillel V, et al. Clinical and pathological response to primary chemotherapy in operable breast cancer. Eur J Cancer 1997; 33: 862-6.CholletPCharrierSBrainECuréHvan PraaghIFeillelVClinical and pathological response to primary chemotherapy in operable breast cancerEur J Cancer199733862610.1016/S0959-8049(97)00038-5Search in Google Scholar
Kuerer HM, Newman LA, Buzdar AU, Dhingra K, Hunt KK, Buchholz TA, et al. Pathologic tumor response in the breast following neoadjuvant chemotherapy predicts axillary lymph node status. Cancer J Sci Am 1998; 4: 230-6.KuererHMNewmanLABuzdarAUDhingraKHuntKKBuchholzTAPathologic tumor response in the breast following neoadjuvant chemotherapy predicts axillary lymph node statusCancer J Sci Am199842306Search in Google Scholar
Goldstein NS, Decker D, Severson D, Schell S, Vicini F, Margolis J, et al. Molecular classification system identifies invasive breast carcinoma patients who are most likely and those who are least likely to achieve a complete pathologic response after neoadjuvant chemotherapy. Cancer 2007; 110: 1687-96.GoldsteinNSDeckerDSeversonDSchellSViciniFMargolisJMolecular classification system identifies invasive breast carcinoma patients who are most likely and those who are least likely to achieve a complete pathologic response after neoadjuvant chemotherapyCancer200711016879610.1002/cncr.22981Search in Google Scholar
Abraham DC, Jones RC, Jones SE, Cheek JH, Peters GN, Knox SM, et al. Evaluation of neoadjuvant chemotherapeutic response of locally advanced breast cancer by magnetic resonance imaging. Cancer 1996: 78: 91-100.AbrahamDCJonesRCJonesSECheekJHPetersGNKnoxSMEvaluation of neoadjuvant chemotherapeutic response of locally advanced breast cancer by magnetic resonance imagingCancer1996789110010.1002/(SICI)1097-0142(19960701)78:1<91::AID-CNCR14>3.0.CO;2-2Search in Google Scholar
Esserman L, Hylton N, Yassa L, Barclay J, Frankel S, Sickles E. Utility of magnetic resonance imaging in the management of breast cancer: evidence for improved preoperative staging. J Clin Oncol 1999; 17: 110-9.EssermanLHyltonNYassaLBarclayJFrankelSSicklesEUtility of magnetic resonance imaging in the management of breast cancer: evidence for improved preoperative stagingJ Clin Oncol199917110910.1200/JCO.1999.17.1.110Search in Google Scholar
Kuhl CK, Schmutzler RK, Leutner CC, Kempe A, Wardelmann E, Hocke A, et al. Breast MR imaging screening in 192 women proved or suspected to be carriers of a breast cancer susceptibility gene: Preliminary results. Radiology 2000; 215: 267-79.KuhlCKSchmutzlerRKLeutnerCCKempeAWardelmannEHockeABreast MR imaging screening in 192 women proved or suspected to be carriers of a breast cancer susceptibility gene: Preliminary resultsRadiology20002152677910.1148/radiology.215.1.r00ap01267Search in Google Scholar
Kriege M, Brekelmans CT, Boetes C, Besnard PE, Zonderland HM, Obdeijn IM, et al. Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. N Engl J Med 2004; 351: 427-37.KriegeMBrekelmansCTBoetesCBesnardPEZonderlandHMObdeijnIMEfficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predispositionN Engl J Med20043514273710.1056/NEJMoa031759Search in Google Scholar
Berg WA, Gutiérrez L, NessAiver MS, Carter WB, Bhargaven M, Lewis RS, et al. Diagnostic accuracy of mammography, clinical examination, US, and MR imaging in preoperative assessment of breast cancer. Radiology 2004; 233: 830-49.BergWAGutiérrezLNessAiverMSCarterWBBhargavenMLewisRSDiagnostic accuracy of mammography, clinical examination, US, and MR imaging in preoperative assessment of breast cancerRadiology20042338304910.1148/radiol.2333031484Search in Google Scholar
Schott AF, Roubidoux MA, Helvie MA, Hayes DF, Kleer CG, Newman LA et al. Clinical and radiologic assessments to predict breast cancer pathologic complete response to neoadjuvant chemotherapy. Breast Cancer Res Treat 2005; 92: 231-8.SchottAFRoubidouxMAHelvieMAHayesDFKleerCGNewmanLAClinical and radiologic assessments to predict breast cancer pathologic complete response to neoadjuvant chemotherapyBreast Cancer Res Treat200592231810.1007/s10549-005-2510-1Search in Google Scholar
Balu-Mastro C, Chapellier C, Bleuse A, Chanalet I, Chauvel C, Largillier R.. Imaging in evaluation of response to neoadjuvant breast cancer treatment benefits of MRI. Breast Cancer Res Treat 2002; 72: 145-52.Balu-MastroCChapellierCBleuseAChanaletIChauvelCLargillierRImaging in evaluation of response to neoadjuvant breast cancer treatment benefits of MRIBreast Cancer Res Treat2002721455210.1023/A:1014856713942Search in Google Scholar
Bodini M, Berruti A, Bottini A, Allevi G, Fiorentino C, Brizzi MP, et al. Magnetic resonance imaging in comparison to clinical palpation in assessing the response of breast cancer to epirubicin primary chemotherapy. Breast Cancer Res Treat 2004; 85: 211-8.BodiniMBerrutiABottiniAAlleviGFiorentinoCBrizziMPMagnetic resonance imaging in comparison to clinical palpation in assessing the response of breast cancer to epirubicin primary chemotherapyBreast Cancer Res Treat200485211810.1023/B:BREA.0000025409.69516.23Search in Google Scholar
Segara D, Krop IE, Garber JE, Wine E, Harris L, Bellon JR, et al. Does MRI predict pathologic tumor response in women with breast cancer undergoing preoperative chemotherapy? J Surg Oncol 2007; 96: 474-80.SegaraDKropIEGarberJEWineEHarrisLBellonJRDoes MRI predict pathologic tumor response in women with breast cancer undergoing preoperative chemotherapy?J Surg Oncol2007964748010.1002/jso.2085617640031Search in Google Scholar
Kim HJ, Im YH, Han BK, Choi N, Choi N, Lee J, Kim JH, et al. Accuracy of MRI for estimating residual tumor size after neoadjuvant chemotherapy in locally advanced breast cancer: relations to response patterns on MRI. Acta Oncol 2007; 46: 996-1003.KimHJImYHHanBKChoiNChoiNLeeJKimJHAccuracy of MRI for estimating residual tumor size after neoadjuvant chemotherapy in locally advanced breast cancer: relations to response patterns on MRIActa Oncol200746996100310.1080/0284186070137358717851879Search in Google Scholar
Fangberget A, Nilsen LB, Hole KH, Holmen MM, Engebraaten O, Naume B, et al. Neoadjuvant chemotherapy in breast cancer response evaluation and prediction to treatment using dynamic contrast-enhanced and diffusion-weighted MR imaging. Eur Radiol 2011; 21: 1188-99.FangbergetANilsenLBHoleKHHolmenMMEngebraatenONaumeBNeoadjuvant chemotherapy in breast cancer response evaluation and prediction to treatment using dynamic contrast-enhanced and diffusion-weighted MR imagingEur Radiol20112111889910.1007/s00330-010-2020-3308880821127880Search in Google Scholar
Dongfeng H, Daqing D, Erhu J. Dynamic breast magnetic resonance imaging: pretreatment prediction of tumour response to neoadjuvant chemotherapy. Clin Breast Cancer 2012; 12: 94-101.DongfengHDaqingDErhuJDynamic breast magnetic resonance imaging: pretreatment prediction of tumour response to neoadjuvant chemotherapyClin Breast Cancer2012129410110.1016/j.clbc.2011.11.00222169574Search in Google Scholar
Nadrljanski MM, Milosevic ZC, Plesinac-Karapandzic V, Maksimovic R. MRI in the evaluation of breast cancer patient response to neoadjuvant chemotherapy: predictive factors for breast conservative surgery. Diagn Interv Radiol 2013; 19: 463-70.NadrljanskiMMMilosevicZCPlesinac-KarapandzicVMaksimovicRMRI in the evaluation of breast cancer patient response to neoadjuvant chemotherapy: predictive factors for breast conservative surgeryDiagn Interv Radiol2013194637010.5152/dir.2013.1320124047722Search in Google Scholar
Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B, Senn HJ. Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 2011; 22: 1736-47.GoldhirschAWoodWCCoatesASGelberRDThürlimannBSennHJStrategies for subtypes-dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011Ann Oncol20112217364710.1093/annonc/mdr304314463421709140Search in Google Scholar
Straver ME, Loo CE, Rutgers EJT, Oldenburg HS, Wesseling J, Vrancken Peeters MJ, et al. MRI model to guide the surgical treatment in breast cancer patients after neoadjuvant chemotherapy. Ann Surg 2010; 251: 701-7.StraverMELooCERutgersEJTOldenburgHSWesselingJVrancken PeetersMJMRI model to guide the surgical treatment in breast cancer patients after neoadjuvant chemotherapyAnn Surg2010251701710.1097/SLA.0b013e3181c5dda320224378Search in Google Scholar
Chen JH, Feig B, Agrawal G, Yu H, Carpenter PM, Mehta RS, et al. MRI evaluation of pathologically complete response and residual tumours in breast cancer after neoadjuvant chemotherapy. Cancer 2008; 112: 17-26.ChenJHFeigBAgrawalGYuHCarpenterPMMehtaRSMRI evaluation of pathologically complete response and residual tumours in breast cancer after neoadjuvant chemotherapyCancer2008112172610.1002/cncr.2313018000804Search in Google Scholar
Williams M, Eatrides J, Kim J, Talwar H; Esposito N, Szabuni M, et al. Comparison of breast magnetic resonance imaging clinical tumor size with pathological tumor size in patients status post-neoadjuvant chemotherapy. Am J Surg 2013; 206: 567-73.WilliamsMEatridesJKimJTalwarHEspositoNSzabuniMComparison of breast magnetic resonance imaging clinical tumor size with pathological tumor size in patients status post-neoadjuvant chemotherapyAm J Surg20132065677310.1016/j.amjsurg.2013.02.00623809673Search in Google Scholar
McGuire KP, Toro-Burguete J, Dang H, Young J, Soran A, Zuley M, et al. MRI staging after neoadjuvant chemotherapy for breast cancer: does tumor biology affect accuracy? Ann Surg Oncol 2011; 18: 3149-54.McGuireKPToro-BurgueteJDangHYoungJSoranAZuleyMMRI staging after neoadjuvant chemotherapy for breast cancer: does tumor biology affect accuracy?Ann Surg Oncol20111831495410.1245/s10434-011-1912-z21947592Search in Google Scholar
Lobbes MB, Prevos R, Smidt M, Tjan-Heijnen VC, van Goethem M, Schipper R, et al. The role of magnetic resonance imaging in assessing residual disease and pathologic complete response in breast cancer patients receiving neoadjuvant chemotherapy: a systematic review. Insights Imaging 2013; 4: 163-75.LobbesMBPrevosRSmidtMTjan-HeijnenVCvan GoethemMSchipperRThe role of magnetic resonance imaging in assessing residual disease and pathologic complete response in breast cancer patients receiving neoadjuvant chemotherapy: a systematic reviewInsights Imaging201341637510.1007/s13244-013-0219-y360995623359240Search in Google Scholar
Ko ES, Han BK, Kim RB, Ko EY, Shin JH, Hahn SY, et al. Analysis of factors that influence the accuracy of magnetic resonance imaging for predicting response after neoadjuvant chemotherapy in locally advanced breast cancer. Ann Surg Oncol 2013; 20: 2562-8.KoESHanBKKimRBKoEYShinJHHahnSYAnalysis of factors that influence the accuracy of magnetic resonance imaging for predicting response after neoadjuvant chemotherapy in locally advanced breast cancerAnn Surg Oncol2013202562810.1245/s10434-013-2925-623463090Search in Google Scholar
Chen JH, Bahri S, Mehta RS, Chen JH, Bahri S, et al. Impact of factors affecting the residual tuor size diagnosed by MRI following neoadjuvant chemotherapy in comparison to pathology. J Surg Oncol 2014; 109: 158-67.ChenJHBahriSMehtaRSChenJHBahriSImpact of factors affecting the residual tuor size diagnosed by MRI following neoadjuvant chemotherapy in comparison to pathologyJ Surg Oncol20141091586710.1002/jso.23470400599424166728Search in Google Scholar
Moon H-G, Han W, Ahn SK, Cho N, Moon WK, Im SA, et al. Breast cancer molecular phenotype and the use of HER2-targeted agents influence the accuracy of breast MRI after neoadjuvant chemotherapy. Ann Surg 2013; 257: 133-7.MoonH-GHanWAhnSKChoNMoonWKImSABreast cancer molecular phenotype and the use of HER2-targeted agents influence the accuracy of breast MRI after neoadjuvant chemotherapyAnn Surg2013257133710.1097/SLA.0b013e3182686bd922968080Search in Google Scholar
Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Thürlimann B, et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol 2013; 24: 2206-23.GoldhirschAWinerEPCoatesASGelberRDPiccart-GebhartMThürlimannBPersonalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013Ann Oncol20132422062310.1093/annonc/mdt303375533423917950Search in Google Scholar
